Form 4 holding
Director
GYRE THERAPEUTICS, INC.
- Security class
- Common Stock
- Shares / value
- 1,636
- Estimated value
- $19,639
- Report date
- 28 Jun 2024
- Price
- $12.00
- Ownership
- Direct
Nassim Usman
Insider Reports History
- Latest reporting-owner signature
-
/s/ Ruoyu Chen, as attorney-in-fact for Nassim Usman
Source: Latest parsed Forms 3/4/5 signature
- Transaction source note
- Rows are grouped by transaction date from the original SEC filing. Open the aggregated insider activity page to review issuer-level activity across dates.
SEC source record
Original filing metadata and source links for verification.
1 source field
Source evidence
Original filing metadata and source links for verification.
1 source field
Reported holdings for Nassim Usman
Form 4 holding
Director
GYRE THERAPEUTICS, INC.
- Security class
- Common Stock
- Shares / value
- 563
- Estimated value
- $6,758
- Report date
- 28 Jun 2024
- Price
- $12.00
- Ownership
- By The Usman Family Trust
Form 4 holding
Director
GYRE THERAPEUTICS, INC.
- Security class
- Common Stock
- Shares / value
- 77
- Estimated value
- $924
- Report date
- 28 Jun 2024
- Price
- $12.00
- Ownership
- By Nassim Usman IRA
Form 4 holding
Director
GYRE THERAPEUTICS, INC.
- Security class
- Stock Option (Right to Buy)
- Shares / value
- 278,200
- Estimated value
- Report date
- 28 Jun 2024
- Price
- Ownership
- Direct
- Underlying class
- Common Stock
- Underlying amount
Form 4 holding
Director
CATALYST BIOSCIENCES, INC.
- Security class
- Series Y Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 31 Aug 2023
- Price
- Ownership
- By Nassim Usman IRA
Form 4 holding
Director
CATALYST BIOSCIENCES, INC.
- Security class
- Series Y Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 31 Aug 2023
- Price
- Ownership
- By The Usman Family Trust
Form 4 holding
Director
CATALYST BIOSCIENCES, INC.
- Security class
- Series Y Preferred Stock
- Shares / value
- 0
- Estimated value
- Report date
- 31 Aug 2023
- Price
- Ownership
- Direct
Insider Reports Filed by Nassim Usman
4
GYRE
GYRE THERAPEUTICS, INC.
- Report period
- 28 Jun 2024
- Transactions
- 3
- Transaction value
- -$17,515
- Accepted by SEC
- 01 Jul 2024, 18:00
- Role
- Director
- Next action
- Open filing details
4
GYRE
GYRE THERAPEUTICS, INC.
- Report period
- 01 May 2024
- Transactions
- 5
- Transaction value
- -$143,977
- Accepted by SEC
- 02 May 2024, 18:19
- Role
- Director
- Next action
- Open filing details
4
GYRE
GYRE THERAPEUTICS, INC.
- Report period
- 01 Apr 2024
- Transactions
- 3
- Transaction value
- -$184,400
- Accepted by SEC
- 03 Apr 2024, 16:01
- Role
- Director
- Next action
- Open filing details
4
GYRE
GYRE THERAPEUTICS, INC.
- Report period
- 15 Mar 2024
- Transactions
- 3
- Transaction value
- -$206,600
- Accepted by SEC
- 19 Mar 2024, 16:47
- Role
- Director
- Next action
- Open filing details
4
GYRE
GYRE THERAPEUTICS, INC.
- Report period
- 31 Oct 2023
- Transactions
- 2
- Transaction value
- $0
- Accepted by SEC
- 01 Nov 2023, 06:15
- Role
- Director
- Next action
- Open filing details
4
GYRE
CATALYST BIOSCIENCES, INC.
- Report period
- 31 Aug 2023
- Transactions
- 3
- Transaction value
- $0
- Accepted by SEC
- 01 Sep 2023, 16:07
- Role
- President & CEO, Director
- Next action
- Open filing details
4
GYRE
CATALYST BIOSCIENCES, INC.
- Report period
- 09 Aug 2022
- Transactions
- 1
- Transaction value
- +$1,528
- Accepted by SEC
- 10 Aug 2022, 17:19
- Role
- President & CEO, Director
- Next action
- Open filing details
4
GYRE
CATALYST BIOSCIENCES, INC.
- Report period
- 09 Feb 2022
- Transactions
- 1
- Transaction value
- +$1,495
- Accepted by SEC
- 16 Feb 2022, 19:13
- Role
- President & CEO, Director
- Next action
- Open filing details
4
GYRE
CATALYST BIOSCIENCES, INC.
- Report period
- 09 Aug 2021
- Transactions
- 1
- Transaction value
- +$3,139
- Accepted by SEC
- 11 Aug 2021, 09:15
- Role
- President & CEO, Director
- Next action
- Open filing details